Read by QxMD icon Read

Ketamine and depression

Wallace C Duncan, Elizabeth E Slonena, Nadia S Hejazi, Nancy Brutsche, Lawrence T Park, Ioline D Henter, Elizabeth D Ballard, Carlos A Zarate
Purpose: This study examined the links between 24-hour activity patterns (specifically, amplitude and timing of wrist activity) and the persisting qualities of clinical antidepressant response to the glutamatergic modulator ketamine. Methods: Twenty-four-hour activity patterns were compared across 5 days of 24-hour activity rhythms in patients with major depressive disorder who displayed either a brief antidepressant response (24-48 hours), a continued antidepressant response (>72 hours), or no antidepressant response to ketamine...
2018: Neuropsychiatric Disease and Treatment
Waguih William IsHak, Raymond Y Wen, Lancer Naghdechi, Brigitte Vanle, Jonathan Dang, Michelle Knosp, Julieta Dascal, Lobsang Marcia, Yasmine Gohar, Lidia Eskander, Justin Yadegar, Sophia Hanna, Antonious Sadek, Leslie Aguilar-Hernandez, Itai Danovitch, Charles Louy
BACKGROUND: Pain comorbid with depression is frequently encountered in clinical settings and often leads to significant impaired functioning. Given the complexity of comorbidities, it is important to address both pain and depressive symptoms when evaluating treatment options. AIM: To review studies addressing pain comorbid with depression, and to report the impact of current treatments. METHOD: A systematic search of the literature databases was conducted according to predefined criteria...
November 2018: Harvard Review of Psychiatry
Andrew Harkin, Declan M McLoughlin
No abstract text is available yet for this article.
November 3, 2018: Brain, Behavior, and Immunity
Natalia Górska, Wiesław Jerzy Cubała, Jakub Słupski, Maria Gałuszko-Węgielnik
Depression is one of the major causes of disability worldwide. A proportion of adults with major depression fail to achieve remission with first-line treatment. Magnesium influences the neurotransmission involved in emotional processes, such as the serotonergic, noradrenergic, dopaminergic, GABAergic and glutamatergic systems. It has been reported that the mechanism of antidepressants' action is involved in the glutamatergic system. Theories about the role of magnesium ions in pathophysiology of major depressive disorder include blocking the glutamatergic N-methyl-D-aspartate receptor (NMDAR)...
May 1, 2018: Magnesium Research: Official Organ of the International Society for the Development of Research on Magnesium
Nihar Ameta, Mathews Jacob, Shahbaz Hasnain, Gaurishankar Ramesh
Background and Aims: Shivering after spinal anesthesia is a common complication and can occur in as many as 40%-70% of patients after regional anesthesia. This shivering, apart from its physiological and hemodynamic effects, has been described as even worse than surgical pain. The aim of the study was to evaluate and compare the effectiveness of prophylactic use of intravenous (IV) ketamine, dexmedetomidine, and tramadol for prevention of shivering after spinal anesthesia. Material and Methods: Two hundred American Society of Anesthesiologists physical status I and II patients subjected to spinal anesthesia were included in the study...
July 2018: Journal of Anaesthesiology, Clinical Pharmacology
Jessica Sexton, Rabia S Atayee, Heather C Bruner
Patients with advanced cancer often suffer from both severe pain and severe symptoms of depression. Use of traditional antidepressants is often limited by the short prognosis associated with advanced cancer. We present the case of a patient with neuropathic pain from advanced cancer and severe depression that responded dramatically to an intravenous infusion of ketamine resulting in decreased pain and resolution of severe depression symptoms.
November 2018: Journal of Palliative Medicine
Yun-Qiang Wan, Jian-Guo Feng, Mao Li, Mao-Zhou Wang, Li Liu, Xueru Liu, Xiao-Xia Duan, Chun-Xiang Zhang, Xiao-Bin Wang
Ketamine has a rapid, obvious, and persistent antidepressant effect, but its underlying molecular mechanisms remain unknown. Recently, microRNAs (miRNAs) have emerged as important modulators of ketamine's antidepressant effect. We investigated the alteration in miR-29b-3p in the brain of rats subjected to ketamine administration and chronic unpredictable mild stress (CUMS), and a sucrose preference test and forced swimming test were used to evaluate the rats' depressive-like state. We used recombination adeno-associated virus (rAAV) or lentivirus-expressing miR-29b-3p to observe the change in metabotropic glutamate receptor 4 (GRM4)...
October 29, 2018: Experimental & Molecular Medicine
Zehong Cao, Chin-Teng Lin, Weiping Ding, Mu-Hong Chen, Cheng-Ta Li, Tung-Ping Su
This study explores the responses to ketamine in patients with treatment-resistant depression (TRD) using a wearable forehead electroencephalography (EEG) device. We recruited 55 outpatients with TRD who were randomized into three approximately equal- sized groups (A: 0.5 mg/kg ketamine; B: 0.2 mg/kg ketamine; and C: normal saline) under double-blind conditions. The ketamine responses were measured by EEG signals and Hamilton Depression Rating Scale (HDRS) scores. At baseline, responders showed a significantly weaker EEG theta power than did non- responders (p < 0...
October 23, 2018: IEEE Transactions on Bio-medical Engineering
Zhongwei Xiong, Kai Zhang, Tamaki Ishima, Qian Ren, Lijia Chang, Jincao Chen, Kenji Hashimoto
The negative allosteric modulators (NAMs: L-655,708 and MRK-016) of α5 subunit-containing GABAA receptors are reported to show rapid-acting antidepressant effects in rodents. However, there are no reports comparing these NAMs and (R)‑ketamine, (R)-enantiomer of the rapid-acting antidepressant ketamine, in a chronic social defeat stress (CSDS) model. Here we measured expression of α5 GABAA receptor in the brain regions from CSDS susceptible mice and postmortem brain samples from depressed patients. Expression of α5 GABAA receptor in the prefrontal cortex and hippocampus from CSDS susceptible mice was significantly higher than that of control mice...
October 23, 2018: Pharmacology, Biochemistry, and Behavior
Yu Yang, Weina Ju, Haining Zhang, Li Sun
Depression is a common mental disorder that is associated with memory dysfunction. Ketamine has recently been demonstrated to be a rapid antidepressant. The mechanisms underlying how depression induces memory dysfunction and how ketamine relieves depressive symptoms remain poorly understood. This work compared three groups of male C57BL/6J mice: mice exposed to chronic social defeat stress (CSDS) to induce a depression-like phenotype, depression-like mice treated with ketamine, and control mice that were not exposed to CSDS or treated with ketamine...
2018: Frontiers in Behavioral Neuroscience
Henrik Michaëlsson, Mats Andersson, Johan Svensson, Lars Karlsson, Johan Ehn, Georgia Culley, Anders Engström, Nicklas Bergström, Parthenia Savvidi, Hans-Georg Kuhn, Eric Hanse, Henrik Seth
AIM: Major depressive disorder is a common and debilitating condition with substantial economic impact. Treatment options, although effective, are aimed at relieving the symptoms with limited disease modification. Ketamine, a commonly used anesthetic, has received substantial attention as it shows rapid antidepressant effects clinically. We studied the effects of ketamine on hippocampal function and dentate gyrus proliferation in rats showing a depressive-like phenotype. METHODS: Adolescent and adult animals were prenatally exposed to the glucocorticoid analog dexamethasone, and we verified a depressive-like phenotype using behavioural tests, such as the sucrose preference...
October 22, 2018: Acta Physiologica
Sonia Vidal, Marianne Gex-Fabry, Victor Bancila, Giorgio Michalopoulos, Delphine Warrot, Françoise Jermann, Alexandre Dayer, Virginie Sterpenich, Sophie Schwartz, Laszlo Vutskits, Nawaz Khan, Jean-Michel Aubry, Markus Kosel
BACKGROUND: Ketamine has been documented for its rapid antidepressant effects. However, optimal dose and delivery route have not yet been thoroughly investigated. The objectives of this study were to document the safety and test the antidepressant and antisuicidal effects of a single rapid 1-minute injection of ketamine 0.5 mg/kg in treatment-resistant depression (TRD). METHODS: Ten patients with TRD were included in an open, noncontrolled 4-week study and received a rapid intravenous dose of ketamine 0...
December 2018: Journal of Clinical Psychopharmacology
G A Mashour, A Ben Abdallah, K O Pryor, R El-Gabalawy, P E Vlisides, E Jacobsohn, E Lenze, H R Maybrier, R A Veselis, M S Avidan
BACKGROUND: Ketamine is a general anaesthetic with anti-depressant effects at subanaesthetic doses. We hypothesised that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients. METHODS: We conducted an international, randomised clinical trial testing the effects of intraoperative administration of ketamine [0.5 mg kg-1 (Lo-K) or 1.0 mg kg-1 (Hi-K)] vs control [saline placebo (P)] in patients ≥60 yr old undergoing major surgery with general anaesthesia...
November 2018: British Journal of Anaesthesia
Katrin Weigmann
No abstract text is available yet for this article.
November 2018: EMBO Reports
Mengxin Shen, Dan Lv, Xu Liu, Shuting Li, Yaping Chen, Yanhua Zhang, Zhen Wang, Chuang Wang
Previous studies have suggested that rapid reductions in depression-like behaviors are observed in response to sub-anesthetic-doses of ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist. Neuropeptide VGF (non-acronymic) is a critical effector of depression-like behaviors and is thought to be involved in the antidepressant actions of ketamine that have been demonstrated. However, the mechanism underlying the involvement of VGF in the anti-depressant action of ketamine remains unclear. We found that single dose ketamine treatment reversed CSDS-induced depression-like behaviors and decrease of VGF in the PFC of mice...
October 11, 2018: Brain Research Bulletin
Leorey N Saligan, Cristan Farmer, Elizabeth D Ballard, Bashkim Kadriu, Carlos A Zarate
BACKGROUND: Fatigue and depression are closely associated. The purpose of this secondary analysis was to understand the relationships between depression and improvements in specific depression domains on the anti-fatigue effects of ketamine, which we previously reported. METHODS: This secondary analysis re-evaluated data collected longitudinally from 39 patients with treatment-resistant Major Depressive Disorder (MDD) enrolled in a double-blind, randomized, placebo-controlled, crossover trial using a single intravenous infusion of ketamine hydrochloride (0...
February 1, 2019: Journal of Affective Disorders
Todd D Gould, Carlos A Zarate, Scott M Thompson
For decades, symptoms of depression have been treated primarily with medications that target the monoaminergic brain systems, which typically take weeks to exert measurable effects and months to exert remission of symptoms. Low, subanesthetic doses of (R,S)-ketamine (ketamine) result in the rapid improvement of core depressive symptoms, including mood, anhedonia, and suicidal ideation, occurring within hours following a single administration, with relief from symptoms typically lasting up to a week. The discovery of these actions of ketamine has resulted in a reconceptualization of how depression could be more effectively treated in the future...
October 8, 2018: Annual Review of Pharmacology and Toxicology
Angeliki Vgontzas, Rebecca Burch
PURPOSE OF REVIEW: To review the pathophysiologic, epidemiologic, and clinical evidence for similarities and differences between migraine with and without aura. RECENT FINDINGS: The ICHD-3 has recently refined the diagnostic criteria for aura to include positive symptomatology, which better differentiates aura from TIA. Although substantial evidence supports cortical spreading depression as the cause of visual aura, the role (if any) of CSD in headache pain is not well understood...
October 5, 2018: Current Pain and Headache Reports
Dawn F Ionescu, Kate H Bentley, Matthias Eikermann, Norman Taylor, Oluwaseun Akeju, Michaela B Swee, Kara J Pavone, Samuel R Petrie, Christina Dording, David Mischoulon, Jonathan E Alpert, Emery N Brown, Lee Baer, Matthew K Nock, Maurizio Fava, Cristina Cusin
BACKGROUND: Several studies indicate that ketamine has rapid antidepressant effects in patients with treatment-resistant depression (TRD). The extent to which repeated doses of ketamine (versus placebo) reduce depression in the short and long term among outpatients with TRD and chronic, current suicidal ideation remains unknown. METHODS: Twenty-six medicated outpatients with severe major depressive disorder with current, chronic suicidal ideation were randomized in a double-blind fashion to six ketamine infusions (0...
January 15, 2019: Journal of Affective Disorders
Chih-Chia Huang, Mang-Hung Tsai, Ya-Chieh Wu, Kuang-Ti Chen, Han-Wen Chuang, Yun Chen, Guan-Woei Tseng, Pin-I Fu, I-Hua Wei
Puerarin is a traditional Chinese medicine with beneficial effects of reduced depression-like behaviors in mice with stress. Previous studies also show that puerarin can produce neuroprotective effect via activating the Akt or increased brain-derived neurotrophic factor (BDNF) expression. Interestingly, BDNF and Akt downstream target, mammalian target of rapamycin (mTOR) mediate the fast-acting antidepressant properties of ketamine. Until now, the involvement of the mTOR signaling pathway or BDNF on puerarin-induced antidepressant effect remains unknown...
October 4, 2018: American Journal of Chinese Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"